指南与共识儿科与产科急症重症综合管理与镇静镇痛

新生儿万古霉素暴露目标与个体化给药建议:模型引导的精准给药

Determination of vancomycin exposure target and individualised dosing recommendations for neonates: model-informed precision dosing.
指南 / 共识 · Int J Antimicrob Agents · 2021-02-07
一句话结论新生儿万古霉素推荐暴露目标为AUC0-24 240–480 mg•h/L(假设MIC=1 mg/L),AUC0-24≥485 mg•h/L为急性肾损伤独立危险因素。

该回顾性观察性队列研究纳入182例新生儿(411个观测点)建立群体药代动力学模型,发现新生儿生理成熟度、肾功能和合并使用血管活性药物显著影响万古霉素药代动力学。7例发生万古霉素相关急性肾损伤,AUC0-24≥485 mg•h/L是校正血管活性药物后急性肾损伤的独立危险因素;42例血培养确诊葡萄球菌脓毒症患者中,AUC0-24/MIC≥234是临床有效的唯一显著预测因子。蒙特卡洛模拟显示Neonatal Formulary 7和Red Book(2018)方案对所有新生儿均不适用。结论推荐新生儿万古霉素暴露目标为AUC0-24 240–480 mg•h/L(假设MIC=1 mg/L),模型引导给药方案具有临床价值。

要点

  • 新生儿万古霉素推荐暴露目标为AUC0-24 240–480 mg•h/L(假设MIC=1 mg/L)。
  • AUC0-24≥485 mg•h/L是校正血管活性药物后新生儿万古霉素相关急性肾损伤的独立危险因素。
  • 血培养确诊葡萄球菌脓毒症新生儿中,AUC0-24/MIC≥234是临床有效的唯一显著预测因子。
  • 新生儿生理成熟度、肾功能和合并使用血管活性药物显著影响万古霉素药代动力学。
  • 蒙特卡洛模拟显示Neonatal Formulary 7和Red Book(2018)方案对所有新生儿均不适用。

适用人群与场景

  • 新生儿,回顾性观察性队列研究纳入182例新生儿进行群体药代动力学建模。
  • 临床疗效分析人群为42例血培养确诊葡萄球菌脓毒症的新生儿。

诊断标准与关键阈值

  • 万古霉素相关急性肾损伤预测阈值:AUC0-24≥485 mg•h/L(校正血管活性药物合并使用后为独立危险因素)。
  • 临床有效性预测阈值:AUC0-24/MIC≥234(唯一显著预测因子)。
  • 推荐暴露目标:AUC0-24 240–480 mg•h/L(假设MIC=1 mg/L)。

处置流程与药物剂量

  • 基于优化暴露目标,采用蒙特卡洛模拟设计给药方案;Neonatal Formulary 7和Red Book(2018)方案对所有新生儿均不适用。

红旗征与不能漏的情况

  • 万古霉素相关急性肾损伤:研究中检测到7例。

研究设计与关键结果

  • 回顾性观察性队列研究,纳入182例新生儿、411个观测点建立群体药代动力学模型;新生儿生理成熟度、肾功能和合并使用血管活性药物显著影响万古霉素药代动力学。
  • 检测到7例万古霉素相关急性肾损伤;AUC0-24≥485 mg•h/L是校正血管活性药物后急性肾损伤的独立危险因素。
  • 42例血培养确诊葡萄球菌脓毒症患者中,AUC0-24/MIC≥234是临床有效的唯一显著预测因子。
  • 蒙特卡洛模拟显示Neonatal Formulary 7和Red Book(2018)方案对所有新生儿均不适用。

证据类型、等级与局限

  • 证据类型:回顾性观察性队列研究(注册号ChiCTR1900027919)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者推荐新生儿万古霉素暴露目标为AUC0-24 240–480 mg•h/L(假设MIC=1 mg/L),模型引导的给药方案在临床实践中有价值。
  • Neonatal Formulary 7和Red Book(2018)方案对所有新生儿均不适用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Few studies incorporating population pharmacokinetic/pharmacodynamic (Pop-PK/PD) modelling have been conducted to quantify the exposure target of vancomycin in neonates. A retrospective observational cohort study was undertaken in neonates to determine this target and dosing recommendations (chictr.org.cn, ChiCTR1900027919).

METHODS: A Pop-PK model was developed to estimate PK parameters. Causalities between acute kidney injury (AKI) occurrence and vancomycin use were verified using Naranjo criteria. Thresholds of vancomycin exposure in predicting AKI or efficacy were identified via classification and regression tree analysis. Associations between exposure thresholds and clinical outcomes, including AKI and efficacy, were analysed by logistic regression. Dosing recommendations were designed using Monte Carlo simulations based on the optimised exposure target.

RESULTS: Pop-PK modelling included 182 neonates with 411 observations. On covariate analysis, neonatal physiological maturation, renal function and concomitant use of vasoactive agents (VAS) significantly affected vancomycin PK. Seven cases of vancomycin-induced AKI were detected. Area under the concentration-time curve from 0-24 hours (AUC0-24) ≥ 485 mg•h/L was an independent risk factor for AKI after adjusting for VAS co-administration. The clinical efficacy of vancomycin was analysed in 42 patients with blood culture-proven staphylococcal sepsis. AUC0-24 to minimum inhibitory concentration (AUC0-24/MIC) ≥ 234 was the only significant predictor of clinical effectiveness. Monte Carlo simulations indicated that regimens in Neonatal Formulary 7 and Red Book (2018) were unsuitable for all neonates.

CONCLUSION: An AUC0-24 of 240-480 (assuming MIC = 1 mg/L) is a recommended exposure target of vancomycin in neonates. Model-informed dosing regimens are valuable in clinical practice.

来源:Int J Antimicrob Agents,查看原文。版权归原作者所有。

参考来源

  1. Tang Z, Guan J, Li J, et al. Determination of vancomycin exposure target and individualised dosing recommendations for neonates: model-informed precision dosing. Int J Antimicrob Agents. 2021. PMID: 33567334. doi:10.1016/j.ijantimicag.2021.106300

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。